- Home
- GOVX vs NCNA Comparison
GOVX vs NCNA Comparison
Compare GOVX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- NCNA
- Stock Information
- Founded
- GOVX 2001
- NCNA 1997
- Country
- GOVX United States
- NCNA United Kingdom
- Employees
- GOVX N/A
- NCNA N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- NCNA Health Care
- Exchange
- GOVX Nasdaq
- NCNA Nasdaq
- Market Cap
- GOVX 7.6M
- NCNA 6.6M
- IPO Year
- GOVX N/A
- NCNA 2017
- Fundamental
- Price
- GOVX $0.68
- NCNA $4.43
- Analyst Decision
- GOVX Strong Buy
- NCNA
- Analyst Count
- GOVX 3
- NCNA 0
- Target Price
- GOVX $10.67
- NCNA N/A
- AVG Volume (30 Days)
- GOVX 690.2K
- NCNA 346.4K
- Earning Date
- GOVX 11-11-2025
- NCNA 08-20-2025
- Dividend Yield
- GOVX N/A
- NCNA N/A
- EPS Growth
- GOVX N/A
- NCNA N/A
- EPS
- GOVX N/A
- NCNA N/A
- Revenue
- GOVX $6,143,044.00
- NCNA N/A
- Revenue This Year
- GOVX N/A
- NCNA N/A
- Revenue Next Year
- GOVX N/A
- NCNA N/A
- P/E Ratio
- GOVX N/A
- NCNA N/A
- Revenue Growth
- GOVX 1943.07
- NCNA N/A
- 52 Week Low
- GOVX $0.43
- NCNA $2.78
- 52 Week High
- GOVX $3.88
- NCNA $1,650.00
- Technical
- Relative Strength Index (RSI)
- GOVX 41.08
- NCNA 47.65
- Support Level
- GOVX $0.65
- NCNA $2.82
- Resistance Level
- GOVX $0.73
- NCNA $3.60
- Average True Range (ATR)
- GOVX 0.04
- NCNA 0.28
- MACD
- GOVX -0.00
- NCNA 0.48
- Stochastic Oscillator
- GOVX 21.28
- NCNA 91.17
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.